semaglutide pancreatitis risk Semaglutide: What we know about safety and cancer Small risk of severe acute

Nat Med (2010) 16(9):10018

La disminucin de los niveles de TNF- e IL-6 indica que la inhibicin de NNMT no solo modula el metabolismo, sino que tambin mejora el microambiente inflamatorio, un componente clave en el desarrollo de enfermedades metablicas y la resistencia a la insulina

Permanence of results Fat dissolving treatments destroy or damage fat cells

Seek urgent medical advice or call 999 if you experience: Chest pain accompanied by breathlessness, sweating, or pain spreading to your arm or jaw these may indicate a cardiac cause and require immediate assessment Vomiting blood or passing black, tarry stools, which may indicate gastrointestinal bleeding Severe or sudden abdominal pain, particularly in the upper abdomen or radiating to the back this could suggest pancreatitis, a rare but recognised risk with GLP-1 receptor agonists (as noted in the SmPCs for semaglutide and tirzepatide) Contact your GP promptly if you experience: Difficulty swallowing (dysphagia) or pain on swallowing (odynophagia) these are red-flag symptoms that require assessment regardless of age Unexplained weight loss beyond what is expected from the medication Persistent nausea or vomiting that is not improving Signs of dehydration following repeated vomiting, including dizziness, reduced urination, or extreme thirst Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice) these may suggest gallbladder disease, a recognised risk with rapid weight loss and GLP-1 receptor agonist therapy NICE NG12 urgent referral criteria: If you are aged 55 or over and have unexplained weight loss alongside upper abdominal pain, reflux, or dyspepsia, your GP should consider an urgent suspected cancer referral